Aging with HIV: a practical review  by Cardoso, Sandra Wagner et al.
b r a z j i n f e c t d i s . 2 0 1 3;1  7(4):464–479
The Brazilian Journal of
INFECTIOUS  DISEASES
www.elsev ier .com/ locate /b j id
Review article
Aging  with  HIV:  a  practical  review
Sandra Wagner Cardoso, Thiago Silva Torres, Marilia Santini-Oliveira, Luana Monteiro
Spindola Marins, Valdiléa Gonc¸alves Veloso, Beatriz Grinsztejn ∗
Fundac¸ão Oswaldo Cruz, Instituto de Pesquisa Clínica Evandro Chagas, HIV/AIDS Clinical Research Center, Rio de Janeiro, RJ, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 14 September 2012
Accepted  21 November 2012









a  b  s  t  r  a  c  t
The worldwide elderly population is expected to grow by an additional 694 million people
by  2025. By that time, there will be approximately two billion elderly people in the world,
most  of whom (80%) will be living in developing countries. Based on recent estimates, this
population  will number over 40 million in 2030 in Brazil and a consequent increase in gov-
ernmental  spending for this population can be expected. Since highly active antiretroviral
therapy  became available in the mid-1990s, the life expectancy of people living with HIV has
increased signiﬁcantly. Approximately 12 million life years were added to the world between
1996  and 2008 as a consequence of wider access to highly active antiretroviral therapy. In
Brazil,  the incidence of AIDS among the population aged ≥50 years doubled between 1996
and  2006. The development of antiretroviral therapy has allowed individuals diagnosed at a
younger age to live longer, which partially explains the aging tendency associated with the
HIV/AIDS  epidemic. It is estimated that by 2015, subjects aged ≥50 years will represent 50%
of  the people living with HIV undergoing clinical treatment. This scenario presents some
challenges, including the fact that the diagnosis of HIV tends to be delayed in older patients
compared  to younger patients because the symptoms of HIV can be confused with those
of  other common diseases among the elderly and also because healthcare professionals do
not consider this population to be at high risk for HIV infection. In regard to the individuals
diagnosed  with HIV, a further challenge is presented by the morbidity normally associated
with  aging. Finally, the elderly also exhibit higher susceptibility to the toxic effects and phar-macological  interactions of medications. The present article reviews the literature regarding
the  proﬁle of HIV infection among individuals aged ≥50 years focusing on practical features
related  to the clinical approach and long-term follow-up of this population.
a  century (1960–2010), life expectancy of the Brazilian popu-
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has  one of the fastest aging populations in the World.2 In half RJ, 21045-900, Brazil.
lation  increased by 25.4 years, having changed from 48.0 to
73.4  years.3 There are currently 15.8 million people aged
60  years or older, and this number is expected to exceed
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Fig. 1 – Comparison of age distribution between people
living  with HIV-AIDS (PLH) and general population (BRPOP)b r a z j i n f e c t d i s .
0 million by 2030.4 It is estimated that the government
xpenses with this population will increase from 38% to
8%  considering the period from 2000 to 2050.5 Since 1998,
he  availability of drugs for the treatment of erectile dysfunc-
ion  has extended the length of the active sex life. Moreover,
lder  individuals have a lower tendency to practice safe sex
han  younger ones.6 This situation may  increase the elderly’s
isk  of human immunodeﬁciency virus (HIV) infection. In addi-
ion, the availability of highly active antiretroviral therapy
HAART) since the mid-1990s has signiﬁcantly increased the
ife  expectancy of people living with HIV (PLH). The worldwide
overage of antiretroviral therapy (ART) increased from 7% in
003 to 42% in 2008.7 Approximately 12 million life years were
dded  to the world between 1996 and 2008 as a result of the
ider  access to HAART.7
During the ﬁrst decade of the acquired immunodeﬁciency
yndrome (AIDS) epidemic, few cases in people aged 50 years
r  older were  reported. However, this number has been
ncreasing steadily.7–11 In Brazil, the incidence of AIDS in this
ge  range doubled between 1996 and 2006.8 The advance of
RT  has increased the life expectancy of individuals diag-
osed  at a young age, which partially explains the aging
endency of the epidemic. It is estimated that by 2015, peo-
le  aged 50 years or older will represent 50% of the PLH
ndergoing clinical treatment.9 This scenario presents some
hallenges,  including the fact that the diagnosis of HIV tends
o  be delayed in older individuals, as some symptoms might
e  confused with those of other common diseases among
he  elderly and because healthcare professionals do not con-
ider  this population to be at high risk of HIV infection. In
egard  to the individuals already diagnosed with HIV, a fur-
her  challenge is presented by the morbidity associated with
ging.  Finally, the elderly also exhibit higher susceptibility to
he toxic effects and pharmacological interactions of medica-
ions.
The  World Health Organization (WHO) and most general
ractitioners and geriatricians deﬁne “elderly” individuals
s  those aged 60 years or older. With regard to PLH, the
S  Centers for Disease Control and Prevention (CDC) con-
ider  “elderly” individuals to be those aged 50 years or
lder.12 Being aged ≥50 years is one of the indications to
tart  HAART according to the Brazilian guideline for ART in
dults.13 The increased prevalence of HIV among older indi-
iduals  has not been accompanied by the formulation of
herapeutic guidelines or recommendations speciﬁc for this
opulation.
The  number of older individuals living with HIV/AIDS is
ncreasing, as a result of a growing number of new HIV diag-
oses  among the elderly as well as the increased survival as
 result of better management. Very scarce data are avail-
ble  about elderly individuals with HIV/AIDS in our setting.
hese  data are important not only to serve as guidance for
he  development of national policies and management guide-
ines  targeting this population but also to guide other low and
iddle  income countries on the several aspects of a reality
hey  will face very soon.
The  aim of the present article is to review the literatureegarding the proﬁle of HIV infection among individuals aged
50  years by focusing on the practical aspects of the clinical
pproach and long-term follow-up of this population.in  Brazil (2010).96
Epidemiological  data
According to the CDC, individuals aged ≥50 years represented
15%  of the newly diagnosed HIV cases, 24% of PLH, 29% of
people  diagnosed with AIDS, and 35% of the deaths caused
by  AIDS in the USA in 2005.11 In Western Europe, 12.9% of
the  new HIV cases reported in 2007 involved individuals aged
≥50  years, which is higher than the rate of 3.7% found in East-
ern  Europe. In Central Europe, the ratio of new cases among
the  elderly to new cases in younger individuals was approxi-
mately  1:10.7
The epidemiological data available for this population in
Latin  America are limited. In Peru, the HIV/AIDS epidemic
mostly affects young people, as 41% of the cases correspond
to  individuals between the ages of 25 and 34.14 The lat-
est  WHO  bulletin does not stratify adult cases by age range
and  does not highlight aging as a speciﬁc topic for this
epidemic.15
In Brazil, a total of 608,230 cases of AIDS were  reported
between 1980 and June of 2011; of these, 64,500 (10.6%) cor-
responded  to individuals older than 50 years, most of whom
were  male (65.0%). The data from this time period show an
increase  in the AIDS incidence rates among individuals older
than  50 years. Among individuals older than 60 years, 10,915
male  and 5923 female cases were reported.8 Data provided
by  the Health Ministry show an increase of 100% in the inci-
dence  of AIDS in this population between 2000 and 2010.
Comparison of age distribution between PLH (age on AIDS
diagnostic) and general population during 2010 in Brazil is
depicted  in Fig. 1. Percentage of individuals in the Brazilian
General Population decreases with age while for PLH in Brazil
the  majority of cases are diagnosed on age strata between 20
and  49 years.
Biology  of  agingThe notion of aging is almost as simple as it is challeng-
ing. Over time physical ﬁtness (vision, hearing, and mobility),
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external appearance (wrinkles and hair loss), and mental
agility  (efﬁciency in the retention and processing of new and
old  information) decline. Although aging is unavoidable, its
progression  is variable. Performance parameters include the
vital  capacity of key organs such as the heart, brain, and
kidneys.  Most body systems exhibit a considerable reserve
capacity,  such that disease-free aging imposes few constraints
on  organ function. Generally, organ function is expected to
decline  by 1% each year beginning at the age of 25.16
The criteria for and deﬁnitions of aging vary so widely
among geriatricians, researchers, and governmental agen-
cies  that there is not even a consensus regarding the “cutoff
point”  for deﬁning “old age.” For the general population,
individuals aged 60–75 years are considered candidates for
monitoring/intervention, and this limit falls to 50 years old
for  PLH.12
Chronological age is the measurement of the years of
life  since birth. The speed of aging depends on genetic fac-
tors,  whereas environmental, biological, and lifestyle-related
factors also inﬂuence the biological or phenotypic age. Senes-
cence,  i.e., the increase in the chronological age of a population
of  predominantly indivisible cells in culture, is an essentially
biological deﬁnition of aging and is considered to be a natu-
ral  process. In contrast, senility corresponds to aging under
pathological circumstances.
Genetic  factors  –  the  role  of  telomeres
All chromosomes of eukaryotic cells include a structure
known as the telomere (from the Greek, telos, end, and
meros,  part), which is a marker of cellular division. Telom-
eres  are a kind of “cap” that protect the ends of chromosomes
and consist of proteins and noncoding DNA. Their func-
tion  is to maintain the structural stability of chromosomes.
Under normal aging conditions, the telomeres shorten at
each  cell division until the cell totally or partially loses its
ability  to divide, leading to disease and death. Telomeres
play the role of a biological clock. The synthesis of telom-
eres  occurs at the end of DNA replication by the action
of  the enzyme telomerase, which is a reverse transcrip-
tase, and telomerase activity depends on the activation of
a  speciﬁc gene that is not activated (“turned on”) in all
cells.
The  role of telomeres in CD4+ T-cell depletion and in clonal
replication of these cells during HIV infection was  described in
1966.17 In HIV+ individuals, the length of telomeres is similar
to  that of non-infected elderly individuals, which might indi-
cate  a predisposition to premature aging. This ﬁnding might
explain  the presence of abnormalities common to the elderly
in  HIV+ younger individuals, such as low numbers of CD4+
T  cells and decreased thymus activity. The physiopathology
of aging in PLH with or without prolonged ART is still poorly
understood. The use of thymidine analogs appears to induce
telomere  shortening.18
The oxidative stress that occurs in natural aging seems
to  favor the replication of HIV, and the presence of HIV, in
turn,  appears to accelerate the natural aging process. Fac-
tors  involved in the progressive loss of the vital (reserve)
capacity of the bodily systems in PLH, leading to organ
failure, reduced cognitive functions, disease, and death 1 3;1  7(4):464–479
include: the presence of comorbidities; viral hepatitis coin-
fection;  alcohol abuse, tobacco, or other drugs; microbial
translocation; and chronic immune dysfunction, in addi-
tion  to the toxicity of ARV agents and other drugs used
concomitantly.19
Effects  of  HIV  infection  and  aging  on  immunity
By itself, aging is associated with complex changes in
the  immune system that increase susceptibility to infec-
tions,  autoimmune and neoplastic diseases, and reduce the
response  to active immunization.20 During the natural pro-
gression  of HIV infection, the immune system is chronically
and  progressively impaired. HIV infection and normal aging
exert  many  similar effects on the immune system. For exam-
ple,  the T-cell population, particularly in the gastrointestinal
tract, is strongly affected by both HIV and aging, as are nearly
all  aspects of immunity.21
B  cells  and  antibody  production
Aging and HIV infection can also affect immunological mem-
ory.  HIV infection is associated with an increased activation of
naïve  B cells, which persists even during the use of HAART.21
Some examples of the B-cell dysfunction that occurs in both
PLH  and older adults include the increased risk of severe bacte-
rial  infections with pathogens such as Streptococcus pneumoniae
and  the reduced ability of polysaccharide antigens to activate
B  cells, demonstrated by a poor response to the pneumococ-
cal  vaccine in terms of the production of efﬁcacious antibodies
and  clinical protection.22
T-cell  function
The number of naïve T cells (CD4+ and CD8+) decreases
with age and HIV infection, and this can also inﬂuence the
effect  of ART.22 The number of such cells is as low in PLH
as  in non-infected individuals aged 20–30 years older. The
T  cells become less responsive, are less able to proliferate,
and  exhibit alterations in the signaling receptors and sur-
face  markers, including a loss of CD28 expression.23 These
changes result in an increase of the Th-2 cells and simulta-
neous  decrease of the Th-1 cells. Consequently, the levels of
interleukin-2  (IL-2), which is produced by Th-1 cells, decreases
as  a result of aging; this phenomenon represents one of the
most  common cytokine alterations observed in immunose-
nescence.
The  number of cytotoxic CD8+ T lymphocytes (CTL)
increases in HIV infection in both young and old individuals.24
The memory  T cells express surface CD28, which stimulates
cell  division in the presence of antigens. “Old” memory  cells
tend  to lose CD28 expression and thus multiply less than
younger  cells upon antigen exposure.25
During chronic HIV infection, the repeated expansion of
the  CD8+ T cell population leads to a loss of CD27 and
CD28  by the T cells, resulting in a predominance of lym-
phocytes that lack the receptors needed for co-stimulation
and efﬁcient antigen presentation. Eventually, the cells attain
replicative  senescence (exhaustion), which is characterized by
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horter telomeres, low telomerase activity, and increased pro-
uction of pro-inﬂammatory cytokines. A high proportion of
D8+  CD28 CTL is predictive of early mortality19 and rapid
rogression to AIDS among PLH,23 although a causal relation-
hip has not yet been established.
The  immune function of the mucous membranes is
everely impaired by HIV infection. Independently of the route
f  infection, HIV replicates more  intensively and the CD4+
 cell population is exhausted much  more  quickly in the
ut-associated lymphoid tissue (GALT) than in the peripheral
lood.  This reduction in the number of CD4+ T cells in the
ALT  does not recover after the onset of HAART as it does in
he  peripheral blood. The effects of aging on the GALT are still
oorly  understood. The consequences of T-cell senescence are
rofound, and the ability to control chronic viral infections is
ost.
ge  and  risk  of  HIV  infection
ew cases of HIV infection among individuals aged ≥50 years
ave  been reported. The CDC estimated that approximately
000 new cases of HIV infection occurred in this population in
he USA in 2009.11 According to an American report with 3000
ndividuals  aged 57–85 years, many  older people are sexually
ctive  on a regular basis (73%, 53% and 26% for 57–64, 65–74
nd  75–85 years, respectively).26 In another study conducted in
he US, 20–30% of men  and women  in their 80s reported being
exually  active.27 Therefore, risky sexual behaviors of individ-
als  ≥50 years of age must be addressed. In a study conducted
n  London (UK) older HIV+ MSM  (men who have sex with men)
re  just as likely to report unsafe sex as younger HIV+ MSM.28
n contrast, a study conducted in the US with HIV+ women ver-
ﬁed that condom use decreased with age while lubricant use
ncreased  with age.29 Older individuals, particularly hetero-
exuals,  might not have an accurate understanding of their
isk  for HIV, most likely as a function of the typical features
f  AIDS at the onset of the epidemic, when AIDS occurred
ostly in young homosexual men. Many  heterosexual individ-
als  ≥50 years are single, have no stable partners, are divorced
r  widowed, and have active sexual lives, often involving part-
ers  who  are also unaware of the need to practice safe sex.
here  seems to be reluctance on the part of both older hetero-
exual  men  and women  to use condoms. Certainly, unwanted
regnancy is not a concern among individuals of this age
ange,  and men  with erectile dysfunction might be particularly
nlikely  to accept condoms.26 Biological mucosa modiﬁca-
ions  subsequent to low estrogen levels causing decreased
ubrication might favor the production of mucosal lesions
hat  increase the risk of HIV transmission. Similarly, biolog-
cal  changes in the anal mucosa make it susceptible to lesions
hat  also facilitate the transmission of HIV.30 The strategies
or  behavioral interventions aimed at promoting the use of
ondoms  among the elderly population must be reassessed.
n  addition, more  recently investigated preventive strategies,
uch  as the treatment of positive partners of serodiscordant
ouples and pre-exposure (PrEP) and post-exposure (PEP) pro-
hylaxis,  need to be assessed because this population might
ave  less access to or may  not be targeted for such preventive
trategies.3;1 7(4):464–479  467
Life  expectancy  and  HIV  infection
Survival estimates for PLH in the period corresponding to the
introduction  of HAART (1996–2005) were  approximately two-
thirds  of the life expectancy of the general population.31 Since
that  time, there have been advances in treatment, including
wider  access to ART and increased knowledge regarding issues
such  as prevention of cardiovascular disease (CVD) and con-
trol  of metabolic diseases in HIV+ individuals. Life expectancy
of  HIV+ individuals is inﬂuenced by social and demographic
factors in addition to their level of immunosuppression. For
example,  the time the CD4+ T-cell count remained below
100  cells/mm3 might be an important predictor of death.32
Nevertheless, the current life expectancy of patients
starting HAART early and thus achieving normal CD4+
counts  sooner might be very similar to that of the general
population.33
HAART  and  aging
Two different scenarios must be taken into account with
regard  to HAART and aging. One situation involves HIV  diag-
nosis  in an individual aged ≥50 years, and the other involves
individuals who have lived with HIV for many  years (chronic
cases)  with complications typically not expected for a given
age  range. PLH include those of all age ranges and may
therefore be exposed to different durations of infection and
different  degrees of toxicity associated with long-term use of
ART.  Therefore, the impact of ART among HIV+ patients start-
ing  treatment after age 50 must be thoroughly understood in
addition to the impact of ARV drugs on the cardiovascular
and metabolic disorders that can be expected in aging people
with  HIV. Interruptions or modiﬁcation of ARV regimens are
often  needed in such patients to minimize drug interactions or
toxicity. In addition, more  thorough or frequent assessments
might be needed in the surveillance of associated morbidi-
ties  and preventive interventions during the follow-up care of
elderly  individuals with HIV.
Clinical  outcomes
In general, the clinical manifestations of immunodeﬁciency
appear late in the course of HIV infection. However, in most
cases,  diagnosis is established only after the immune sys-
tem  has been strongly affected and CD4+ T-cell count is
less  than 200 cells/mm3. Older people are diagnosed at more
advanced  stages of HIV infection than younger individuals.34
This delayed diagnosis might partially explain some stud-
ies’  ﬁndings of poorer clinical outcomes, including shorter
intervals between the identiﬁcation of HIV, the AIDS diagno-
sis  and reduced length of survival,7 in elderly patients than
in  younger patients. Healthcare professionals do not seem
overly  concerned with the possibility of HIV infection in older
individuals,  possibly because older people are less likely than
younger  people to be considered sexually active or intravenous
drug  users. In addition, many  of the symptoms of HIV infection
might  be confused with signs of natural aging, such as weight
loss,  fatigue, and cognitive or visual problems.35 The older
i s . 2 0468  b r a z j i n f e c t d 
patients themselves also may  not suspect of their HIV infec-
tion.  Most individuals diagnosed with HIV after age 60 never
suspected  that they were  infected before they were tested.36
Studies conducted in the pre-HAART era found an associa-
tion  between old age and the risk of death among HIV infected
individuals.37 At the beginning of the HAART era, access to
ART  was  identiﬁed as the only factor associated with survival
in  patients older than 50 years.38 Improvement of ART efﬁcacy
has  been correlated with longer life expectancy among indi-
viduals  with HIV infection, and it is estimated that 50% of the
currently  treated population will be aged ≥60 years in 2015.39
Early  mortality
Early mortality risk after the HIV infection diagnosis increases
with  age. A CDC survey on 12-, 24-, and 36-month survival
after  diagnosis showed that mortality was  substantially higher
among  older patients at all three time points assessed.40 A
study  comparing early mortality between the cities of Rio de
Janeiro  and Baltimore also found a higher risk of death among
the  elderly (hazard ratio (HR) 1.03; p = 0.03).41
Immune  response  to  HAART  and  viral  suppression
In terms of the CD4+ T cell count improvement and viral sup-
pression  at different age ranges, most studies found that older
people  can achieve success rates similar to younger individ-
uals  given adherence to HAART.42,43 Greenbaum et al. found
that  the average time to attain the ﬁrst undetectable viral load
(VL)  was  lower among patients aged ≥50 years than patients
aged  ≤40 years (3.2 vs. 4.4 months; p = 0.001). This difference
was  more  signiﬁcant when HAART included one protease
inhibitor (PI).44
Nevertheless, the immune recovery rate can be slower and
less  robust among older patients. Data from the NA-ACCORD
cohort study showed that the probability of recovering the
CD4+  T-cell count (an increase of at least 100 cells/mm3 over
the  ﬁrst two years of ART) decreased with age.45 Low treat-
ment  compliance does not seem to explain these outcomes
because older patients exhibit better adherence than younger
patients  and have a lower risk of viral rebound.46
Selection  of  ART  regimens
It is recommended that individual ART regimens take the
patient’s  lifestyle, among other factors, into account. Age is
also an important factor for the selection of ART. Nucleoside
analogs are strongly associated with mitochondrial toxicity,
and  zidovudine (ZDV) causes bone marrow suppression. Older
patients  might exhibit reduced renal function and loss of bone
mass  in addition to depression and cognitive disorders. There
is  more  information regarding aging patients with HIV infec-
tion  that have been exposed to ART for long periods of time
than  information regarding how to treat an old HIV+ patient
recently  diagnosed. Moreover, the choice to start treatment
for  individuals who have a diagnosis in the age groups above
50–60  years is probably something new for most clinicians. As
the proportion of older patients starting treatment increases, 1 3;1  7(4):464–479
studies  assessing the efﬁcacy and tolerability of regimens for
this particular population are needed.
Tolerability  to  ART
Due to greater need for concomitant medications in older
patients,  elderly HIV+ patients are expected to have poorer
tolerability to ART, higher toxicity, and more  numerous drug
interactions. However, there are currently few data regarding
these  aspects.47 In the Swiss cohort, older patients tended
to  use more  concomitant medications than younger patients
and  also exhibited higher risks of drug interactions, which
were  mostly related to the effects of ART on the action of
the  concomitant medications. Toxic effects most commonly
described are associated with gastrointestinal intolerance, fol-
lowed  by central nervous system disorders, hepatotoxicity,
and dyslipidemia.48
There is little information regarding the reasons to change
ART  in the elderly population. Among 95 patients aged
≥50  years in the IPEC/Fiocruz cohort starting their ﬁrst HAART
regimen  between January 1996 and December 2008, 59%
modiﬁed  or discontinued (MOD) the ﬁrst regimen (28.1/100
individuals per year of follow-up); the mean time to MOD  was
12  months, and the main reasons for MOD were  therapeu-
tic  failure (14%), toxicity during the ﬁrst year of HAART (11%),
and  long-term toxicity (6%). The incidence of MOD  was  signif-
icantly  higher among patients who started HAART with CD4+
T-cell  counts < 100 cells/mm3 (HR 1.97; 95% conﬁdence inter-
val  (CI) 1.08–3.61).49 In a German cohort, a change of regimen
was  more  common among patients aged ≥50 years.50
Adherence,  resistance  and  drug  interactions
Some studies found higher adherence to ART among patients
aged  ≥50 years compared to younger patients.46,51
Data regarding the resistance proﬁle in therapeutic failure
among  elderly patients are scarce, as are data on pri-
mary  resistance and age. In a German cohort, no difference
was  found in transmission of resistance between older and
younger  patients.50 In an Italian cohort, increased age was
independently associated with higher likelihood of primary
resistance.52
Older patients tend to have more  comorbidities, fall ill more
often,  and pharmacological intervention is frequently needed,
with  a consequent high risk of drug interactions. Older HIV+
patients  use more  medications for CVD, gastrointestinal, and
hormonal  problems than younger patients, whose use of these
medications  matches that of the general population.48 In the
Swiss  cohort, age was  one of the risk factors associated with
increased  drug interactions.53
Non-AIDS-deﬁning  illnesses  associated  with
HIV
HAART reduced AIDS-related morbidity and mortality; how-
ever,  the death rate among HIV+ individuals attributed
to  non-AIDS-deﬁning illnesses, including liver, lung, car-
diovascular, and neoplastic diseases, increased.54 Many
such  illnesses correlate with HIV after adjustment for
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ell-established demographic and behavioral risk factors.
ome examples include myocardial infarction, thrombosis,
nd  stroke; bone diseases, including osteoporosis and avas-
ular  necrosis; neoplasias caused by infectious agents such
s  human papillomavirus (HPV)-related anal cancer; and
eoplasias  not caused by infectious agents, such as lung
ancer;  chronic obstructive pulmonary disease, dementia,
iver  ﬁbrosis progressing into cirrhosis, and hepatocarcinoma;
ematologic diseases such as anemia and thrombocytopenia;
nd kidney dysfunction, including end-stage failure.54
Chronic immunosuppression has been associated with
any  such conditions in large cohort studies, where low CD4+
-cell  counts are predictive of death by non-AIDS-deﬁning
utcomes. The incidence of such conditions is higher among
eople  aged ≥50 years.23
Some authors have disputed the correlation between
IV/HAART and the early appearance of comorbidities based
n  the predominance of retrospective analyses among these
tudies  and the lack of sufﬁcient data regarding well-
stablished risk factors such as smoking, abuse of alcohol and
ecreational  drugs, socioeconomic status, and concomitant
edications.55
alignancies
he higher incidence of malignancies in PLH is related to the
hronic  oncogenic effect of some viral infections but is not
ecessarily  related to aging. Nevertheless, some important
spects related to HIV, age, and the incidence of neoplasias
re  still controversial, such as whether HIV leads to early
ccurrence of cancer, whether the high incidence of some
alignancies among PLH is a consequence of accelerated
ging, and whether all patients should be treated with HAART
pon  diagnosis of HIV infection to achieve steady viral sup-
ression  and maintain immunity close to its normal status.
owever,  it is unclear whether avoiding severe immunodeﬁ-
iency alone reduces the risk of HIV-related malignancies.56
Predictive factors of non-AIDS-deﬁning malignancies
nclude age (the risk rate doubles per ten years of age
ncrease); the most recent low CD4+ T-cell count; a history of
moking,  and hepatitis B (HBV) coinfection.57 HAART is pro-
ective  against AIDS-deﬁning malignancies but does not seem
o  protect against non-AIDS-deﬁning malignancies.57 Some
tudies  have shown that since HAART was  introduced, non-
IDS-deﬁning malignancies have been diagnosed earlier in
IV/AIDS patients.57,58 PLH might also be at a higher risk of
ancer  due to peculiarities of their lifestyle, particularly smok-
ng  and use of alcohol.56
As the HIV+ population ages while exhibiting persistent
lterations of the immune system, an increasing number of
alignancies  can be expected over time. Lung, anal, and
iver  cancer, as well as Hodgkin’s lymphoma, represent the
ain  contributions to this increase. In the US, the incidence
f  breast, colon, and prostate cancer is lower among HIV+
ndividuals than among the general population; this may  be
ecause  the HIV+ individuals had not reached a sufﬁcient
ge  to develop such malignancies or to some protective effect
elated  to HIV.56
In any case, the prevention and early treatment of neo-
lasias  in PLH must be included in public health follow-up3;1 7(4):464–479  469
strategies and therapeutic guidelines targeting the elderly
population.
Frailty
Frailty is a pathologic aging syndrome, the mechanism of
which  is unknown, that leads to unfavorable outcomes such as
hospitalization, disability, and death.59 Increased free radical
levels,  mitochondrial dysfunction, and cytokines might acti-
vate  inﬂammatory pathways, leading to this condition. The
levels  of C-reactive protein, d-dimer, ﬁbrinogen, and IL-6 are
increased  in older individuals with the frailty phenotype.60
Similarly, HIV infection and ART toxicity activate the inﬂam-
matory  mechanisms associated with frailty.59 There is no
universal  deﬁnition of “frailty” for patients with HIV/AIDS;
in  the general population, a frailty phenotype is established
when at least three of the following traits are present: exhaus-
tion,  slow walking speed, low levels of physical activity,
weakness, and weight loss.60 HIV infection seems to acceler-
ate  the development of frailty, even when the patient exhibits
viral  suppression under HAART. In addition to HIV, frailty
has  also been associated with age, the female gender, a low
level  of schooling, being single, abuse of non-prescription
drugs, and depressive symptoms. Table 1 describes an algo-
rithm  for the calculation of frailty that can be applied to
patients.
Fat,  metabolic,  hormonal  disorders  and  cardiovascular
disease
HIV infection is associated with a higher risk of metabolic
disorders such as insulin resistance, pro-atherogenic lipid pro-
ﬁles, and alterations of the subcutaneous and visceral body fat
distribution  (lipodystrophy). Such disorders might contribute
to  the higher risk of CVD associated with HIV and ART.61
Some cross-sectional studies have found an increased risk
of  metabolic and hormonal disorders, including osteopenia,
hypogonadism, diabetes mellitus, and dyslipidemia.62,63 In the
Swiss  cohort, a higher proportion of non-AIDS comorbidities
and  multiple morbidities such as diabetes mellitus and CVD
were  observed among older individuals.64
The earliest cohort studies associated HIV infection and
exposure  to ART with a risk of coronary disease and myocar-
dial  infarction (MI). Subsequently, Friis-Moller et al. found
that  the risk of MI  was  more  strongly associated with pre-
established risk factors such as advanced age.65 Nevertheless,
the  correlation among HIV infection, inﬂammation, and car-
diovascular  risk has not yet been fully elucidated.66 HIV
infection, prolonged ART, and aging are known to contribute
to  lipoatrophy and metabolic disorders.67 In the American
VACS cohort, the risk of MI was  twice as high among the
HIV+  than the non-infected individuals, even after adjusting
for  established risk factors such as age, race, hypertension,
diabetes mellitus, hypercholesterolemia, smoking, infection
with  hepatitis C virus (HCV), kidney disease, body mass
index  (BMI), and history of cocaine and alcohol abuse.
However, the age at which MI occurred did not differ sig-
niﬁcantly among the older individuals, regardless of HIV
status.68
470  b r a z j i n f e c t d i s . 2 0 1 3;1  7(4):464–479
Table 1 – Frailty calculation.81,82
Criteria Deﬁnition Positive
Unintentional weight loss ≥5% of previous body weight OR > 4.5 kg of body weight loss in the last year. –
Low physical activity Health limits vigorous activities such as running, lifting heavy objects or
participating in strenuous sports.
Options:
(1)  Not at all;
(2)  Yes, limited a little;
(3)  Yes, limited a lot.
(3)  Yes, limited a lot
Low resistance/exhaustion In the last week, how often the patient felt that everything s/he did was an
effort OR s/he could not ‘get going’.
Options:
(0)  Rarely (<1 day);
(1)  Some of the time (1–2 days);
(2)  Occasionally (3–4 days);
(3)  Most of the time (5–7 days)
(2)  Occasionally
(3–4 days) or
(3)  Most of the time
(5–7  days).
Serial strength test Highest pressure strength (dynamometer Jamar = 3 attempts) 20% weaker stratiﬁed by
sex  and BMI
Slow walking time Time to walk 4 min in an usual place. 20% slower by sex and
railtyFrailty Positive for 3 or more criteria (pre-f
Renal  function
Renal function is reduced in both elderly and PLH, leading
to  an impaired elimination of drugs and an increased risk of
toxicity  and mortality associated with CVD.69 Although the
survival  of PLH with end-stage kidney disease has improved
since  the introduction of HAART, its incidence has not
changed.69 The survival rates of elderly patients undergoing
dialysis are low, and a delay in the initiation of dialysis is asso-
ciated  with even greater morbidity and mortality. It is not yet
known  whether the control of arterial pressure and glycemia
might  delay the progression of kidney disease in HIV+ patients
as  it does in the general population.69
Liver  disease
Liver disease is an important cause of death among PLH,
surpassed only by opportunistic infections. Morbidity and
mortality  due to liver disease are up to 4-fold higher among
the  elderly than among young adults. In addition, the liver vol-
ume,  blood ﬂow, drug metabolism, and regenerative capacity
decrease  with age. Age is also associated with greater risk of
hepatocellular  carcinoma. The progression of chronic hepati-
tis  C into cirrhosis is accelerated in HIV+ patients.70
Cognitive  impairment  and  HIV
The natural history of HIV infection is changing, and fac-
tors  associated with advanced age will become an important
modulator of its clinical outcomes, particularly dementia.
Historically, there was  no need to consider the poten-
tial  contribution of age-related neurodegenerative diseases
such  as Alzheimer’s to cognitive disorders among PLH
because  HIV primarily affected young individuals, whose
life  expectancy was  then low. With the advance of HAART,
there  is an increased likelihood that young and middle-agedmedium  height
: 1–2; normal: 0)
HIV+  individuals will develop premature neurodegenerative
disorders that could directly impact their ability to work and
reduce  their quality of life.71 Increased longevity under con-
ditions  of chronic HIV-mediated inﬂammation combined with
the  secondary effects of HAART might signiﬁcantly contribute
to  the increased risk of early cerebral aging and cognitive loss.
Although  the incidence of HIV-related dementia decreased
after  HAART was  introduced, several studies reported a corre-
lation  between old age and an increased risk of HIV-associated
dementia as the initial AIDS-deﬁning illness.32
Smoking
The well-established risks of smoking are considered greater
among  PLH, as these risks may  be enhanced by the chronic
inﬂammation associated with HIV, even among individuals
with  appropriate viral suppression. Associated questions
include whether PLH smokers are at a higher risk of lung
cancer  or other malignancies as well as cardiovascular com-
plications  compared to smokers in the general population. As
PLH are aging, their risk for all age-related diseases, includ-
ing  malignancies, will increase. The impact of being a smoker
among  HIV+ individuals who are aging needs to be estab-
lished,  once the prevalence of smokers among PLH is high,
ranging  from 50 to 70%.72
Vitamin  D  deﬁciency
Although the rate of vitamin D deﬁciency is high among
PLH73,74 little is known about the beneﬁts of vitamin D
supplements in metabolic disorders other than those involv-
ing  the bones. The available data are controversial and
non-standardized. In addition, the ideal replacement and
maintenance regimes for PLH are not known. It is also impor-
tant  to highlight that bone diseases, depression and cognitive


























Table 2 – Routine measures used in the general population that must be incorporated into the preventive care and health maintenance of individuals living with
HIV/AIDS (PLH).83–95
Comorbidity Risk factors Preventive measures
Anal cancer • Infection by human papillomavirus (HPV) • The anti-HPV recommendations are currently the same as those
established for the general population and might have a future
impact; however, recommendations speciﬁcally for the HIV-infected
population are still being established, and several strategies are
currently being studied. Screening for anal cancer prevents invasive
cancer by means of the identiﬁcation and removal of precancerous
lesions (high-grade anal intraepithelial neoplasia – HGAIN) before
their progression. Initial screening tests usually include a digital rectal
examination, visual inspection, and anal cytology. When abnormal,
patients are referred for high-resolution anoscopy and biopsy of
lesions suspected of HGAIN. HGAIN areas are removed by ablation to
reduce the risk of progression into anal cancer. Cost-effectiveness
studies of these strategies are currently being conducted.
Arterial hypertension • Gender: until menopause, women are more protected




•  Contraceptives (women aged > 35 years)
•  Smoking
•  Use of alcohol
•  Nutritional habits (high salt consumption)
• Low socioeconomic level
•  Pre-hypertension (systolic arterial pressure – SAP = 120–139 mmHg or
diastolic  arterial pressure –  DAP = 80–89 mmHg): Increased attention to
lifestyle  habits such as eating a healthy diet and exercising regularly.
• Hypertension stage I (SAP = 140–159 mmHg or DAP = 90–99 mmHg):
thiazide diuretics. Also consider the use of angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, beta-blockers,
calcium-channel blockers, or a combination of these.
• Hypertension stage II (SAP ≥ 160 mmHg or DAP ≥ 100 mmHg):
combination of 2 anti-hypertensive agents
Breast cancer • Personal or familial history of breast cancer
• No children
•  Signiﬁcant exposure to X-rays
•  Early menarche
•  Late menopause
•  High socioeconomic class
•  First pregnancy after age 30
•  Fat-rich diet
•  Prolonged use of oral contraception (disputed)
• Clinical and self-examinations
•  Refer to gynecologist for periodical assessment
• Mammography
• Ultrasound




•  Lung cancer screening; early assessment when symptoms are
present
• Smoking cessation
•  Preliminary data suggest that thorax computed tomography with



























Table 2 – (Continued ).
Comorbidity Risk factors Preventive measures
Cardiovascular disease and stroke • Smoking
•  Sedentarism
•  Dyslipidemia
•  Menopause (women)
•  Glucose intolerance
•  Familial history
•  Obesity (BMI > 30 kg/m2)
• Abdominal obesity (men > 94 cm, women > 80 cm)
• Metabolic syndrome
•  HIV infection appeared as an independent risk factor; however,
risk increases when CD4+ count is low and VL is persistently high
(loss of virologic control).
•  1st step – assess CVD risk: Framingham scale
• Use of aspirin (dose according to coronary disease risk calculated by
Framingham score)
•  Control of blood pressure
•  Control of cholesterol
•  Smoking cessation
•  Control of diabetes and prediabetes
•  Aerobic physical exercise (30 min, 3–5 days/week)
• Balanced diet to maintain healthy body weight: fruits, vegetables,
whole grains, ﬁber-rich foodstuffs, ﬁsh (especially oily ﬁsh twice a
week)
• Restrict saturated fat to <7% of daily intake, trans fat to 1%, and
cholesterol to <300 mg/day.
• Reduce consumption of sodas and foodstuffs containing added
sugar.
• Choose and prepare foodstuffs with little salt.
• Use alcohol moderately.
Colon/bowel cancer • Familial history of colorectal cancer
• Diet high in fat and meat and low in calcium
• Obesity
•  Sedentarism
•  Inﬂammatory bowel disease
•  Colonoscopy; screening starting at age 50 is recommended for the
general population
•  Smoking cessation
Dementia/Alzheimer’s disease • Familial history • Cognitive exercises
•  Dementia after stroke: lifestyle changes, including regular physical
exercise, a balanced diet, and the control of high blood pressure and
diabetes mellitus
•  Alzheimer’s disease: no prevention is available
Diabetes mellitus
Normal  glycemia: <100 mg/dL fasting or
<140 mg/dL 2 hours after intake of 75 g of dextrose
Prediabetes: 100–120 mg/dL fasting or
140–200 mg/dL after dextrose
Diabetes Mellitus: fasting glycemia ≥ 126 mg/dL,
>200  mg/dL after dextrose or casual glycemia, or
>200 mg/dL when symptoms are present
• Age equal to or older than 45 years (HIV non-infected individuals)
• Familial history
•  Sedentarism




•  Previous gestational diabetes
•  Children with birth weights higher than 4 kg, repetitive
abortions, children dying during the ﬁrst days of life
• Use of medications that increase glucose (cortisone, thiazide
diuretics, beta-blockers)
•  HIV-infected patients using ART exhibit a fourfold higher risk.
• Diet control/planning
•  Physical exercise
•  Weight loss
•  Restricted use of alcohol
•  Glycemic control
•  Smoking cessation
•  Avoid pancreas-damaging medications (cortisone, thiazide
diuretics).
• Pharmacological treatment: metformin is the ﬁrst choice and might
be associated with sulfonylureas
•  Insulin might be needed as an adjuvant of oral drugs or as a second
choice because it improves insulin resistance and has possible effects
on the lipids and body composition. Risk of hypoglycemia


























Table 2 – (Continued ).
Comorbidity Risk factors Preventive measures
Dyslipidemia Types of dyslipidemia:
• Isolated hypercholesterolemia: low-density lipoprotein –
LDL-C ≥ 160 mg/dL
•  Isolated hypertriglyceridemia: TG ≥ 150 mg/dL
• Mixed hyperlipidemia: LDL-C ≥ 160 mg/dL and TG ≥ 150 mg/dL
simultaneously
• Low HDL: isolated reduction of HDL-C (<40 mg/dL in males and
<50  mg/dL in females) or associated with increased LDL-C or TG
•  Changes in lifestyle: regular physical exercise, weight loss, smoking
cessation, nutritional therapy
•  Isolated hypercholesterolemia: statins (LDL-C reduction; lower TG
reduction; slight HDL-C increase); ezetimibe (combined with a statin).
Use cautiously in patients using ART due to the risk of interactions.
Simvastatin and lovastatin cannot be used due to interaction with
ART.
• Mixed hyperlipidemia (increased cholesterol, LDL-C and TG): ﬁbrates
(bezaﬁbrate, ciproﬁbrate, fenoﬁbrate, and gemﬁbrozil). Caution is
needed due to interaction with ART; nicotinic acid; omega-3 fatty
acids.
• Elderly: attention to secondary causes of dyslipidemia, mainly
hypothyroidism, diabetes mellitus, and chronic kidney failure
Hepatitis A (HAV) Intake of contaminated water
Lack  of basic sanitation
•  Personal hygiene (intake of treated water, washing hands, avoiding
foodstuffs of unknown origin)
•  Basic sanitation: (sewage, septic tanks)
Laboratory test for HAV markers (anti-HAV IgM and anti-HAV IgG)
• Vaccination: schedule for susceptible individuals (non-reagent HAV
IgG serology) – 2 doses (at 0 and 6–12 months or 0 and 6–18 months).
Not included in the Handbook for CRIE – Health Ministry (Brazil)
• Lower response to vaccine in individuals with CD4+ < 200
Hepatitis B (HBV) • Multiple sexual partners
•  Healthcare professionals
•  Patients undergoing hemodialysis
•  Injection drug use
•  Use of condoms
•  Universal precautions with biological materials
• Laboratory tests for HBV markers (HBsAg, anti-HBs, anti-HBc IgM,
anti-HBc)
Vaccination: 4 double-dose applications (at 0, 1, 2, and 6 months)
• Butantan (Brazil): Up to 18 years old: 1 mL; ≥ 19 years old: 2 mL
• Lower response to vaccine in cases of advanced immunodeﬁciency,
patients with detectable viral load, and those with transiently
increased viral load. Measurement of anti-HBs is recommended
(4–6 weeks after the last vaccine dose) because revaccination might be
needed.
Hepatitis  C (HCV) • Multiple sexual partners
•  Injection drug and inhalants use
•  Use of condoms
•  Universal precautions with biological materials
• Not sharing needles and other tools used in the preparation and
consumption of injectable drugs and inhalants (straws)
• Laboratory tests for HCV markers (anti-HCV)
Liver cancer • Alcoholism
•  HCV and HBV coinfection
•  Careful monitoring of patients with chronic HBV and HCV infection;
treatment when indicated, periodic assessment of the liver function,
viral load, and possibly alpha-fetoprotein


























Table 2 – (Continued ).
Comorbidity Risk factors Preventive measures
Metabolic syndrome Characterized by
• Glucose ≥ 100 mg/dL
•  Triglycerides ≥ 150 mg/dL
•  Blood pressure ≥ 130/85 mmHg
•  HDL cholesterol < 50 mg/dL (men) or <40 mg/dL (women)
•  Abdominal circumference > 80 cm (women) and >94 cm (men)
•  Diet
• Regular physical exercise
•  Lipid proﬁle
•  BMI reduction to 18.5–24.9 kg/m2
Osteopenia/osteoporosis • Female gender (menopause)
•  Smoking
•  Low calcium intake
•  Vitamin D deﬁciency
•  Vitamin A excess
•  Sedentarism
•  High caffeine intake
•  High salt consumption
•  Immobilization
•  Falls
•  Alcohol (more than 3 drinks/day)
•  Low BMI
•  Osteoporosis is diagnosed by means of BMD measurements
using dual-energy X-ray absorptiometry (DXA) of the hips and
lumbar spine. The measurements are expressed as g/cm2 for the
same age and gender (Z score) and for same-gender young adults
(T score). The WHO deﬁnes osteoporosis as a T score ≤ −2.5, which
does not apply to women before menopause, men younger than 50
years, and children. In such cases, the diagnosis is based on ≤−2.0,
which means BMD below the ‘normal’ BMD expected for age and
gender, suggesting the need to investigate pathological causes.
• Calcium intake: women aged > 50 years = 1200 mg/day (supplements:
600 mg of elemental calcium + 200 IU or 400 IU of cholecalciferol)
•  Vitamin D: adults aged > 50 years = 800–1000 IU/day of vitamin D3
(cod liver oil, fortiﬁed milk, egg yolk, fresh salmon, canned tuna,
canned sardine)
•  Exercises that increase muscle strength against gravity
(bodybuilding, local exercises, etc.)
• Prevention of falls
•  Smoking cessation
•  Avoid excessive alcohol consumption.
Avoid  the use of steroids and proton-pump inhibitors.
Pharmacological treatment:
-  Antiresorptive agents: bisphosphonates (alendronate, risedronate,
ibandronate, zoledronic acid); selective estrogen receptor modulators
(raloxifene); hormonal therapy
-  Bone forming or anabolic: teriparatide
- Bone forming/antiresorptive: strontium ranelate
The use of calcium and bisphosphonates is recommended in cases of
fractures or BMD T score < 2.5 standard deviations.
Prostate cancer • Familial history
•  Afro-descendants
•  Fat-rich diet
•  Prostate assessment (digital rectal exam – DRE)
• Assessment of the blood prostate-speciﬁc agent (PSA) levels
• Transrectal ultrasound
•  Diet low in fat and high in protein, fruits, vegetables, and legumes
• The American Urological Association recommends PSA and DRE in
asymptomatic men aged 40 years or older when the life expectancy is
greater than 10 years. This recommendation is currently being
updated.
• The American Cancer Society recommends that men at average risk
be given information starting at age 50 and black men and those with
familial history of prostate cancer at age 45.
• The American College of Preventive Medicine recommends that
general practitioners discuss the potential beneﬁts and risks of PSA
screening with men aged 50 years or older while taking the patients’
preferences into account and making individual screening decisions.
• Guidelines for HIV-infected patients are being established. Earlier



























Table 2 – (Continued ).
Comorbidity Risk factors Preventive measures
Renal function • Age
•  Diabetes
•  CVD
•  Deﬁcient nutrition
•  HIV: directly or indirectly causes several types of kidney
disorders such as nephropathy, thrombotic microangiopathy,
immune-mediated glomerulonephritis
•  Some ART agents might cause or exacerbate pre-existing
nephropathy.
• Verify the glomerular ﬁltration rate (GFR):
Grade 1: Kidney alterations with normal or increased GFR;
GFR > 90 mL/min/1.73 m2
Grade 2: Kidney alterations with slightly decreased GFR;
GFR = 30–59 mL/min/1.73 m2
Grade 3: Moderate reduction of GFR; GFR = 30–59 mL/min/1.73 m2
Grade 4: Severe reduction of GFR; GFR = 15–29 mL/min/1.73 m2
Grade 5: Kidney failure; GFR < 15 mL/min/1.73 m2 (or under dialysis)
• Avoid combinations of nephrotoxic drugs.
• Smoking and alcoholism cessation and a healthy diet
• Treat dyslipidemia and diabetes.
•  Adjust dose of medications when needed.
Skin cancer • Light skin • Use of sun protection
•  Avoidance of excessive sun exposure
Uterine cancer • Social factors (low socioeconomic class)
• Habits (poor hygiene; prolonged use of oral contraceptives)
• Sexual activity and pregnancy before age 18
• Smoking (directly related with the number of cigarettes)
Infection by HPV and herpes virus type 2 (HSV-2)
• Multiple sexual partners
•  Annual preventive cervical cancer exam (Papanicolaou, test)
• For cervical cancer screening, the Pap smear must be performed
during anogenital examination after the diagnosis of HIV, with a
second Pap smear six months later and then once a year when the
results are normal.
•  Colposcopy in indicated cases: whenever Pap is abnormal
• HPV testing as a cervical cancer screening method in HIV-infected
women might also be efﬁcacious.
Vaccination Vaccination decisions depend on the clinical and vaccination
history of patients.
The  response to vaccines is better in patients with
CD4+ > 350 cells/mm3. Assess the best time to vaccinate the
patient,  but do not delay the onset of vaccination in high-risk
patients.
Inactivated vaccines have no restrictions in immunodeﬁcient
individuals. Attenuated vaccines must only be used when the
potential beneﬁt outweighs the risk and only in patients with
CD4+ > 200 cells/mm3.
Some vaccines might transiently increase the viral load without
clinical consequences. It is recommended to vaccinate during the
intervals between viral load tests.
•  Inactivated DT: Basic schedule: 3 doses (at 0, 2, and 4 months;
booster: 1 dose every 10 years)
•  Inﬂuenza: 1 dose every year
•  Pneumococcus (Streptococcus pneumoniae) – inactivated pneumo
23-valent: 1 intramuscular or subcutaneous dose with a single booster
5  years later; vaccination reduces the risk of pneumonia and invasive
disease
• Attenuated varicella: susceptible adults with CD4+ > 200 cells/mm3:
2 doses with a 4–8-week interval
•  HPV: tetravalent (HPV 16, 18, 6, 11) – ideally, vaccinate both males
and females between the ages of 9 and 26 (3 doses: 0, 2, and 6
months). Not available in the Brazilian public health network, and its
cost is high. Use is safe in HIV-infected individuals; however,
cost-effectiveness studies must be performed in this population.
• Attenuated yellow fever: upon traveling to risk area. When
CD4+ > 200 cells/mm3: 1 dose every 10 years
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D deﬁciency. Therefore, controlled trials assessing both the
success  of vitamin D replacement and its beneﬁts are needed.
Bone  mass  loss
HIV causes chronic activation of T cells and increases the
production  of pro-inﬂammatory cytokines, which increase
the  activity of osteoclasts, and these alterations persist
despite effective ART and viral suppression.75 The current
understanding of bone metabolism in the aging HIV/AIDS
population is limited, and the sparse longitudinal data avail-
able  show conﬂicting results.76 Despite the currently limited
understanding of the factors associated with bone mineral
reduction, the assessment of risk factors for bone loss is
needed  to reduce the morbidity of osteopenia and osteoporo-
sis  in the HIV+ aging population.
Women  with  HIV/AIDS  and  menopause
A study conducted in Germany found that women reported
more  age-related complaints (such as mood swings and
impaired  mobility) than men, and 80% of the women believed
that  they were  aging prematurely, compared to 18% of men
(p  < 0.001).77 Early menopause seems to be related to HIV-
induced immunodeﬁciency and is more  common among
women  with low CD4+ T-cell counts. Risk factors described
and  established for the general female population, such
as  African descent and a history of intravenous drug use,
have  been associated with early menopause among HIV+
women.78 In turn, early menopause inﬂuences the overall
health  of women  and might be associated with reduced
sexual function and depressive symptoms in addition to
increased  cardiovascular risk and skeletal health issues.
Recently, higher rate of bone mass loss was  found in the
spine  and forearms of postmenopausal HIV+ women  com-
pared  to non-infected women, independent of stable ART.79
The loss of bone mass is likely to increase the risk of frac-
tures  in this population. Therefore, stratiﬁcation of risk by
means  of bone densitometry and research on secondary
causes of osteoporosis and its appropriate treatment in all
postmenopausal HIV+ women seems justiﬁed. The useful-
ness  of such assessments in younger women has not yet been
established.
Routine  measures  that  should  be  incorporated
into the  preventive  care  and  health
maintenance of  older  individuals  living  with
HIV/AIDS
Regular physical exercise is extremely important to the quality
of  life of PLH, especially older individuals. A study per-
formed in São Paulo, Brazil, found that resistance training
increased the strength of older patients and allowed them
to  achieve the same level of performance as the healthy
control patients, even when their initial clinical proﬁle was
80worse.
In addition to physical exercise, other healthy habits such
as  eating a balanced diet; controlling the blood pressure; treat-
ing  diabetes and dyslipidemia; and abstaining from smoking,
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alcohol, and drugs, must be strongly encouraged in PLH, par-
ticularly  among the older. Routine measures applied to the
general  population that should be incorporated into the pre-
ventive  care and health maintenance of PLH are described in
Table  2.
Conclusion
Health care and prevention guidelines tailored to elderly HIV+
individuals  are needed. The higher prevalence of comor-
bidities, polypharmacy, drug interactions, and end-organ
disease in this patient population requires a multidisciplinary
approach. Longitudinal studies are needed to assess the actual
impact  of HIV on aging and vice versa. In addition, HIV preven-
tion  strategies targeted to older adults should be considered.
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